<unk>  is a human monoclonal IgG1λ antibody that is FDA approved for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.   Common adverse reactions include upper respiratory infections, headache, injection site reactions, arthralgia, diarrhea, gastroenteritis, tinea infections, and herpes simplex infections.
Guselkumab
Ustekinumab
Nebacumab
Evolocumab
Dupilumab
Alirocumab
Burosumab
Sarilumab